Loading
Life sciences · Journal article
BMC Cancer · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab has become a standard treatment for patients with early-stage triple-negative breast cancer (TNBC) based on the KEYNOTE-522 trial; however, real-world data on event-free survival (EFS) remain limited. We aimed to evaluate EFS of this regimen and explore the association between immune-related adverse events (irAEs) and EFS. We retrospectively reviewed patients with early-stage TNBC or estrogen receptor-low, HER2-negative breast cancer receiving neoadjuvant pembrolizumab plus chemotherapy at our institution between October 2022 and September 2024. EFS was defined as the time from initiation of neoadjuvant therapy to disease progression, local or distant recurrence, second primary cancer, or death from any cause. EFS was estimated using the Kaplan–Meier method, with log-rank test comparisons. A total of 95 patients were included, with a median age of 52 years. Median follow-up was 24.2 months. Overall pathological complete response (pCR) rate was 62.1%. The estimated 12- and 24-month EFS rates were 96.8% and 88.0% in the overall population, 100.0% and 97.3% in the pCR cohort, and 91.7% and 75.3% in the non-pCR cohort, respectively. EFS was significantly longer in the pCR cohort than in the non-pCR cohort, and all EFS events in the non-pCR cohort occurred within 21 months. Grade 3/4 irAEs occurred in 14 patients, among whom no EFS events were observed during follow-up. This study demonstrated EFS outcomes broadly comparable with those reported in the KEYNOTE-522 trial. The absence of EFS events among patients with severe irAEs was a descriptive, hypothesis-generating observation that warrants further investigation.